Literature DB >> 1354343

Pertussis toxin pretreatment abolishes the inhibitory effect of riluzole and carbachol on D-[3H]aspartate release from cultured cerebellar granule cells.

A Doble1, J P Hubert, J C Blanchard.   

Abstract

The release of D-[3H]aspartate from cultured cerebellar granule cells evoked by glutamic acid can be inhibited by riluzole and the muscarinic agonist carbachol. The combined application of maximally efficacious concentrations of riluzole and carbachol produces no greater inhibition than that seen with either agent alone, indicating that a common mechanism is involved. The effects of both agents are abolished when the cells have been pretreated with pertussis toxin, which suggests that this mechanism may involve a GTP-binding protein. The effect of pertussis toxin pretreatment is not mimicked by cholera toxin, nor does pertussis toxin pretreatment interfere with the inhibitory effect of the competitive excitatory amino acid receptor antagonist D-alpha-aminoadipic acid.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1354343     DOI: 10.1016/0304-3940(92)90114-m

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  14 in total

1.  Patterns of cortical activity differ in ALS patients with limb and/or bulbar involvement depending on motor tasks.

Authors:  Katja Kollewe; Thomas F Münte; Amir Samii; Reinhard Dengler; Susanne Petri; Bahram Mohammadi
Journal:  J Neurol       Date:  2010-12-03       Impact factor: 4.849

2.  Targeting glial physiology and glutamate cycling in the treatment of depression.

Authors:  Gerald W Valentine; Gerard Sanacora
Journal:  Biochem Pharmacol       Date:  2009-04-17       Impact factor: 5.858

Review 3.  Glutamate, excitotoxicity and amyotrophic lateral sclerosis.

Authors:  P J Shaw; P G Ince
Journal:  J Neurol       Date:  1997-05       Impact factor: 4.849

4.  Effects of riluzole on electrically evoked neurotransmitter release.

Authors:  T Jehle; J Bauer; E Blauth; A Hummel; M Darstein; T M Freiman; T J Feuerstein
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

Review 5.  Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis.

Authors:  H M Bryson; B Fulton; P Benfield
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

Review 6.  Motor neuron disease.

Authors:  P N Leigh; K Ray-Chaudhuri
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-08       Impact factor: 10.154

7.  Inhibition by riluzole of glycinergic postsynaptic currents in rat hypoglossal motoneurones.

Authors:  M Umemiya; A J Berger
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

8.  Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole.

Authors:  Brian P Brennan; James I Hudson; J Eric Jensen; Julie McCarthy; Jacqueline L Roberts; Andrew P Prescot; Bruce M Cohen; Harrison G Pope; Perry F Renshaw; Dost Ongür
Journal:  Neuropsychopharmacology       Date:  2009-12-02       Impact factor: 7.853

Review 9.  Riluzole in the treatment of mood and anxiety disorders.

Authors:  Christopher Pittenger; Vladimir Coric; Mounira Banasr; Michael Bloch; John H Krystal; Gerard Sanacora
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

10.  Antagonism by riluzole of entry of calcium evoked by NMDA and veratridine in rat cultured granule cells: evidence for a dual mechanism of action.

Authors:  J P Hubert; J C Delumeau; J Glowinski; J Prémont; A Doble
Journal:  Br J Pharmacol       Date:  1994-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.